Overview

• Study reveals a significant rise in prescriptions for GLP-1 agonists like Wegovy and Ozempic among individuals aged 12 to 25 from 2020 to 2023.
• Young women and adolescent girls show the highest increase in prescriptions.
• Experts emphasize the importance of safe and appropriate prescribing practices for these medications.
• Obesity and type 2 diabetes rates among young people have been climbing, prompting more aggressive treatment approaches.
• Concerns include the high cost and limited insurance coverage for these medications, as well as potential side effects.